Paul Kirschmeier Selected Research

lonafarnib (SCH 66336)

12/2009	Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
4/2008	Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
9/2007	Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
7/2007	Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
9/2005	The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
5/2004	Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
1/2003	Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.
8/2002	Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul Kirschmeier Research Topics

Disease

24	Neoplasms (Cancer) 01/2019 - 04/2002
5	Breast Neoplasms (Breast Cancer) 01/2019 - 04/2005
3	Lung Neoplasms (Lung Cancer) 01/2021 - 03/2014
3	Ovarian Neoplasms (Ovarian Cancer) 04/2008 - 06/2003
2	Melanoma (Melanoma, Malignant) 01/2018 - 07/2013
2	Retinoblastoma (Glioblastoma, Retinal) 10/2017 - 08/2010
2	Fever (Fevers) 10/2017 - 05/2004
2	Carcinogenesis 09/2008 - 02/2002
2	Diarrhea 07/2007 - 05/2004
1	Adenocarcinoma of Lung 01/2019
1	Ovarian Epithelial Carcinoma 01/2019
1	Nausea 01/2019
1	Hypotension (Low Blood Pressure) 10/2017
1	Pancytopenia 10/2017
1	Hyperuricemia 10/2017
1	Orthostatic Hypotension (Postural Hypotension) 10/2013
1	Prostatic Neoplasms (Prostate Cancer) 12/2009
1	Hematologic Neoplasms (Hematological Malignancy) 12/2009
1	Brain Neoplasms (Brain Tumor) 07/2007
1	Central Nervous System Neoplasms 07/2007
1	Neutropenia 05/2004
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2004
1	Peripheral Nervous System Diseases (PNS Diseases) 05/2004
1	Leukemia 01/2003

Drug/Important Bio-Agent (IBA)

8	lonafarnib (SCH 66336)IBA 12/2009 - 08/2002
5	Farnesyltranstransferase (Farnesyltransferase)IBA 12/2009 - 05/2004
5	TransferasesIBA 04/2008 - 02/2002
3	Cell-Free Nucleic AcidsIBA 01/2018 - 03/2014
3	dinaciclibIBA 10/2017 - 08/2010
3	Taxoids (Taxanes)IBA 10/2011 - 01/2006
3	Proteins (Proteins, Gene)FDA Link 04/2008 - 02/2002
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 07/2013
2	MK-8353IBA 07/2018 - 01/2018
2	Aromatase InhibitorsIBA 01/2018 - 09/2007
2	SCH772984IBA 01/2018 - 07/2013
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 10/2017 - 10/2013
2	Docetaxel (Taxotere)FDA Link 12/2009 - 09/2005
2	Hormones (Hormone)IBA 12/2009 - 09/2007
2	Paclitaxel (Taxol)FDA LinkGeneric 04/2008 - 05/2004
2	Tamoxifen FDA LinkGeneric 09/2007 - 09/2005
2	Small Interfering RNA (siRNA)IBA 05/2007 - 04/2005
2	taxaneIBA 09/2005 - 05/2004
2	Complementary DNA (cDNA)IBA 04/2005 - 06/2003
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2021
1	Alanine Transaminase (SGPT)IBA 01/2019
1	olaparibIBA 01/2019
1	AlpelisibIBA 01/2019
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2019
1	ArginaseIBA 01/2019
1	Complement System Proteins (Complement)IBA 01/2019
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	3(S)-thiomethyl pyrrolidineIBA 07/2018
1	Transaminases (Aminotransferases)IBA 10/2017
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 03/2014
1	DNA (Deoxyribonucleic Acid)IBA 03/2014
1	Uric Acid (Urate)IBA 10/2013
1	Mitogen-Activated Protein KinasesIBA 07/2013
1	SCH 1473759IBA 10/2011
1	Bromodeoxyuridine (BrdU)IBA 08/2010
1	Monomeric GTP-Binding ProteinsIBA 09/2008
1	rho GTP-Binding Proteins (rho GTP-Binding Protein)IBA 09/2008
1	p21(ras) farnesyl-protein transferase (protein farnesyltransferase)IBA 04/2008
1	Estrogen Receptor Modulators (Antiestrogen)IBA 09/2007
1	Anastrozole (Arimidex)FDA LinkGeneric 09/2007
1	Aromatase (CYP19)IBA 09/2007
1	Loperamide (Imodium)FDA LinkGeneric 07/2007
1	Biomarkers (Surrogate Marker)IBA 05/2007
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 05/2007
1	Protein Isoforms (Isoforms)IBA 05/2007
1	Phosphotransferases (Kinase)IBA 05/2007
1	Messenger RNA (mRNA)IBA 04/2006
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 04/2006
1	LigandsIBA 04/2006
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 04/2006
1	Biological ProductsIBA 03/2003
1	SurvivinIBA 04/2002
1	Inhibitor of Apoptosis ProteinsIBA 04/2002

Therapy/Procedure

2	Therapeutics 07/2018 - 02/2014
1	Aftercare (After-Treatment) 04/2008